OBJECTIVES: Although a growing number of treatment options are available for metastatic breast cancer (mBC), each treatment is associated with its own various advantages and disadvantages. It remains unclear how patients value the different treatment characteristics and whether preferences vary as a function of prior treatment experience.  METHODS: Data were collected through a cross-sectional Internet survey of 181 women diagnosed with mBC who had prior experience with either a taxane, paclitaxel, or docetaxel.  Patients provided demographic, health history, and health outcomes information. Participants also completed a choice-based conjoint exercise that included a series of choice questions.  Each choice question included a pair of hypothetical treatments which were presented in terms of eight safety attributes (alopecia, motor neuropathy, myalgia/arthralgia, nausea/vomiting, fatigue, neutropenia, mucositis/stomatitis, and diarrhea), one effectiveness attribute, one dosing regimen attribute, and one quality of life attribute.  Choice task data were analyzed using hierarchical Bayesian logistic regression models. Relative importances (RI) were reported and provide the magnitude of each attribute’s influence on treatment preference on a common ratio scale (e.g., an RI of 50% is twice as influential as an RI of 25%).  RESULTS:  Women had a mean age of 52.24 years and 93.92% were non-Hispanic white.  Effectiveness (RI=33.49%) was most strongly associated with treatment preference, followed by alopecia (RI=21.32%), fatigue (RI=12.46%), neutropenia (RI=10.37%), and quality of life (RI=7.69%).  Myalgia (RI=0.48%), mucositis (RI=0.43%), and dosing regimen (RI=0.14%) had the weakest associations with preference.  These preferences did not vary as a function of chemotherapy experience. CONCLUSIONS: Despite the risk of serious adverse events, incremental survival (1-3 months) is  influential in patient prefer­ences for chemotherapy. Furthermore, quality of life improvements were more influential in treatment preferences than most adverse events. These findings help clarify the patient perspective of mBC treatments which, if aligned with prescribing patterns, may maximize treatment satisfaction and adherence.